49 results on '"Saudeau D"'
Search Results
2. Initially isolated Hornerʼs syndrome: A multicenter series of 0.90 dissections: SC202
- Author
-
De Bray, J-M., Baumgartner, R., Pautot, V., Guillon, B., Dziewas, R., Ringelstein, E. B., Garnier, P., Ducrocq, X., Saudeau, D., Neau, J.-P., Larrue, V., Vuillier, F., Bouilliat, J., Verret, J.-M., Verny, C., and Dubas, F.
- Published
- 2004
3. Comparative study of atrial vulnerability in patients with unexplained ischemic stroke or lone atrial paroxysmal fibrillation
- Author
-
Rouesnel, P, Babuty, D, Fauchier, L, Saudeau, D, Hurreesing, R, Cosnay, P, and Garnier, L.-F
- Published
- 2003
- Full Text
- View/download PDF
4. Cervical Artery Dissections in the Puerperium: Pathogenic Hypotheses Concerning Seven Observations
- Author
-
de Bray, J. M., Guillon, B., Neau, J. P., Bouilliat, J., Ducrocq, X., Saudeau, D., Vincent, D., Penisson-Besnier, I., Pasco, A., and Dubas, F.
- Published
- 2000
- Full Text
- View/download PDF
5. Paraneoplastic opsoclonus associated with cancer of the gall bladder
- Author
-
Corcia, P, de Toffol, B, Hommet, C, Saudeau, D, and Autret, A
- Published
- 1997
6. How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease.
- Author
-
European Huntington's Disease Initiative Study Group, the Multicentre Intracerebral Grafting in Huntington's Disease Group, Bachoud-Lévi, AC., Boissé, MF., Lemoine, L., Verny, C., Aubin, G., Demonet, JF., Calvas, F., Krystkowiak, P., Simonin, C., Delliaux, M., Damier, P., Renou, P., Supiot, F., Slama, H., Guillamo, J., Dürr, A., Bloch, F., Messouak, O., Tallaksen, C., Dubois, B., Engles, A., Destee, A., Memin, A., Thibaut-Tanchou, S., Pasquier, F., Galitzky, M., Rascol, O., Mollion, H., Broussolle, E., Madigand, M., Lallement, F., Goizet, C., Tison, F., Arguillère, S., Bakchine, S., Khoris, J., Camu, W., Resch, F., Hannequin, D., Durif, F., Saudeau, D., Autret, A., Schramm, C., Katsahian, S., Youssov, K., Démonet, J.F., Cleret de Langavant, L., Bachoud-Lévi, A.C., European Huntington's Disease Initiative Study Group, the Multicentre Intracerebral Grafting in Huntington's Disease Group, Bachoud-Lévi, AC., Boissé, MF., Lemoine, L., Verny, C., Aubin, G., Demonet, JF., Calvas, F., Krystkowiak, P., Simonin, C., Delliaux, M., Damier, P., Renou, P., Supiot, F., Slama, H., Guillamo, J., Dürr, A., Bloch, F., Messouak, O., Tallaksen, C., Dubois, B., Engles, A., Destee, A., Memin, A., Thibaut-Tanchou, S., Pasquier, F., Galitzky, M., Rascol, O., Mollion, H., Broussolle, E., Madigand, M., Lallement, F., Goizet, C., Tison, F., Arguillère, S., Bakchine, S., Khoris, J., Camu, W., Resch, F., Hannequin, D., Durif, F., Saudeau, D., Autret, A., Schramm, C., Katsahian, S., Youssov, K., Démonet, J.F., Cleret de Langavant, L., and Bachoud-Lévi, A.C.
- Abstract
The retest effect-improvement of performance on second exposure to a task-may impede the detection of cognitive decline in clinical trials for neurodegenerative diseases. We assessed the impact of the retest effect in Huntington's disease trials, and investigated its possible neutralization. We enrolled 54 patients in the Multicentric Intracerebral Grafting in Huntington's Disease (MIG-HD) trial and 39 in the placebo arm of the Riluzole trial in Huntington's Disease (RIL-HD). All were assessed with the Unified Huntington's Disease Rating Scale (UHDRS) plus additional cognitive tasks at baseline (A1), shortly after baseline (A2) and one year later (A3). We used paired t-tests to analyze the retest effect between A1 and A2. For each task of the MIG-HD study, we used a stepwise algorithm to design models predictive of patient performance at A3, which we applied to the RIL-HD trial for external validation. We observed a retest effect in most cognitive tasks. A decline in performance at one year was detected in 3 of the 15 cognitive tasks with A1 as the baseline, and 9 of the 15 cognitive tasks with A2 as the baseline. We also included the retest effect in performance modeling and showed that it facilitated performance prediction one year later for 14 of the 15 cognitive tasks. The retest effect may mask cognitive decline in patients with neurodegenerative diseases. The dual baseline can improve clinical trial design, and better prediction should homogenize patient groups, resulting in smaller numbers of participants being required.
- Published
- 2015
7. Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease
- Author
-
Cubo, E, González, M, del Puerto, I, de Yébenes, Jg, Arconada, Of, Gabriel Galán, Jm, Ehdi, Sg, Zangerl, A, Seppi, K, Wenning, G, Poewe, W, Foeldy, D, Auff, E, Schober, T, Wenzel, K, Ott, E, Walli, J, Leblhuber, F, Dürr, A, Bloch, F, Messouak, O, Tallaksen, C, Dubois, B, Guillamo, Js, Bachoud Lévi, Ac, Engles, A, Krystkowiak, P, Destée, A, Memin, A, Thibaut Tanchou, S, Pasquier, F, Azulay, Jp, Demonet, Jf, Galitzky, M, Rascol, O, Mollion, H, Broussolle, E, Madigand, M, Lallement, F, Goizet, C, Tison, F, Arguillère, S, Viallet, F, Bakchine, S, Khoris, J, Pages, M, Camu, W, Resch, F, Hannequin, D, Durif, F, Saudeau, D, Autret, A, Andrich, J, Saft, C, Kraus, Ph, Przuntek, H, Ecker, D, Kramer, B, Landwehrmeyer, Gb, Ludolph, Ac, Priller, J, Meierkord, H, Kuznik, D, Dose, M, Squitieri, F, Albanese, A, Abbruzzese, Giovanni, Filla, A, van de Warrenburg, B, de Jong, D, Kremer, H, van Vugt, J, Grimbergen, Y, Roos, R, Gawel, M, Janik, P, Kowalczys, H, Pilczuk, B, Kwiecinski, H, Świat, M, Ochudło, S, Modestowicz, R, Niezgoda, A, Łukasik, M, Lukasik, M, García Ruiz, P, Descals, Am, Rojo, A, Fontán, A, Hernández, J, Cantarero, S, Fanjul, S, Alegre, J, Roldán, Sg, Mateo, D, Burguera, Ja, Solis, P, Calopa, M, Jaumà, S, Bas, J, Tolosa, E, Muñoz, Je, Gámez, J, Cervera, C, Zarranz, Jj, Lezcano, E, Gómez, Jc, Chacón, J, Dinca, L, Gamero, Ma, Redondo, L, Castro, A, Sesar, A, López del Val, J, López, E, Ríos, C, Castillio, V, Burgunder, Jm, Nirkko, A, Kälin, A, Vingerhoets, F, and Wider, C.
- Published
- 2012
8. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
- Author
-
Hacke, Werner, Kaste, Markku, Bluhmki, Erich, Brozman, Miroslav, Dávalos, Antoni, Guidetti, Donata, Larrue, Vincent, Lees, Kennedy R., Medeghri, Zakaria, Machnig, Thomas, Schneider, Dietmar, Von Kummer, Rüdiger, Wahlgren, Nils, Toni, Danilo, Hacke, W, Dávalos, A, Kaste, M, von Kummer, R, Larrue, V, Toni, D, Wahlgren, N, Lees, Kr, Heiss, Wd, Lesaffre, E, Orgogozo, Jm, Bastianello, S, Wardlaw, Jm, Peyrieux, Jc, Sauce, C, Medeghri, Z, Mazenc, R, Machnig, T, Bluhmki, E, Aichner, F, Alf, C, Baumhackl, U, Brainin, M, Eggers, C, Gruber, F, Ladurner, G, Niederkorn, K, Noistering, G, Willeit, J, Vanhooren, G, Blecic, S, Bruneel, B, Caekebeke, J, Laloux, P, Simons, Pj, Thijs, V, Bar, M, Dvorakova, H, Vaclavik, D, Boysen, G, Andersen, G, Iversen, Hk, Traberg-Kristensen, B, Marttila, R, Sivenius, J, Trouillas, P, Amarenco, P, Bouillat, J, Ducrocq, X, Giroud, M, Jaillard, A, Larrieu, Jm, Leys, D, Magne, C, Mahagne, Mh, Milhaud, D, Sablot, D, Saudeau, D, Busse, O, Berrouschot, J, Faiss, Jh, Glahn, J, Görtler, M, Grau, A, Grond, M, Haberl, R, Hamann, G, Hennerici, M, Koch, H, Krauseneck, P, Marx, J, Meves, S, Meyding-Lamadé, U, Ringleb, P, Schneider, D, Schwarz, A, Sobesky, J, Urban, P, Karageorgiou, K, Komnos, A, Csányi, A, Csiba, L, Valikovics, A, Agnelli, G, Billo, G, Bovi, P, Comi, G, Gigli, G, Guidetti, D, Inzitari, D, Marcello, N, Marini, C, Orlandi, G, Pratesi, M, Rasura, M, Semplicini, A, Serrati, C, Tassinari, T, Brouwers, Pj, Stam, J, Naess, H, Indredavik, B, Kloster, R, Czlonkowska, A, Kuczyńska-Zardzewialy, A, Nyka, W, Opala, G, Romanowicz, S, Cunha, L, Correia, C, Cruz, V, Pinho e Melo, T, Brozman, M, Dvorak, M, Garay, R, Krastev, G, Kurca, E, Alvarez-Sabin, J, Chamorro, A, del Mar Freijo Guerrero, M, Herrero, Ja, Gil-Peralta, A, Leira, R, Martí-Vilalta, Jl, Masjuan Vallejo, J, Millán, M, Molina, C, Mostacero, E, Segura, T, Serena, J, Vivancos Mora, J, Danielsson, E, Cederin, B, Von, Zweigberg, Wahlgren, Ng, Welin, L, Lyrer, P, Bogousslavsky, J, Hungerbühler, Hj, Weder, B, Ford, Ga, Jenkinson, D, Macleod, Mj, Macwalter, Rs, Markus, Hs, Muir, Kw, Sharma, Ak, Walters, Mr, Warburton, Ea, ACS - Amsterdam Cardiovascular Sciences, ANS - Amsterdam Neuroscience, and Neurology
- Subjects
Adult ,Male ,Time Factors ,medicine.medical_treatment ,Placebo ,Drug Administration Schedule ,Brain Ischemia ,Brain ischemia ,Double-Blind Method ,Fibrinolytic Agents ,Modified Rankin Scale ,medicine ,Odds Ratio ,Desmoteplase ,Humans ,Infusions, Intravenous ,Stroke ,Aged ,business.industry ,Cerebral infarction ,Medicine (all) ,General Medicine ,Thrombolysis ,Middle Aged ,medicine.disease ,Logistic Models ,Treatment Outcome ,Anesthesia ,Tissue Plasminogen Activator ,Acute Disease ,Female ,business ,Intracranial Hemorrhages ,Fibrinolytic agent - Abstract
Background Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have not been established. We tested the efficacy and safety of alteplase administered between 3 and 4.5 hours after the onset of a stroke. Methods After exclusion of patients with a brain hemorrhage or major infarction, as detected on a computed tomographic scan, we randomly assigned patients with acute ischemic stroke in a 1:1 double-blind fashion to receive treatment with intravenous alteplase (0.9 mg per kilogram of body weight) or placebo. The primary end point was disability at 90 days, dichotomized as a favorable outcome (a score of 0 or 1 on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms at all and 6 indicating death) or an unfavorable outcome (a score of 2 to 6 on the modified Rankin scale). The secondary end point was a global outcome analysis of four neurologic and disability scores combined. Safety end points included death, symptomatic intracranial hemorrhage, and other serious adverse events. Results We enrolled a total of 821 patients in the study and randomly assigned 418 to the alteplase group and 403 to the placebo group. The median time for the administration of alteplase was 3 hours 59 minutes. More patients had a favorable outcome with alte plase than with placebo (52.4% vs. 45.2%; odds ratio, 1.34; 95% confidence interval [CI], 1.02 to 1.76; P = 0.04). In the global analysis, the outcome was also improved with alteplase as compared with placebo (odds ratio, 1.28; 95% CI, 1.00 to 1.65; P
- Published
- 2008
9. Weight loss in Huntington disease increases with higher CAG repeat number
- Author
-
Aziz, Na, van der Burg, Jm, Landwehrmeyer, Gb, Brundin, P, Stijnen, T, Ehdi, Sg, Roos, Ra, Zangerl, A, Seppi, K, Wenning, G, Poewe, W, Foeldy, D, Auff, E, Schober, T, Wenzel, K, Ott, E, Walli, J, Leblhuber, F, Dürr, A, Bloch, F, Messouak, O, Tallaksen, C, Dubois, B, Guillamo, Js, Bachoud Lévi, Ac, Engles, A, Krystkowiak, P, Destée, A, Memin, A, Thibaut Tanchou, S, Pasquier, F, Azulay, Jp, Demonet, Jf, Galitzky, M, Rascol, O, Mollion, H, Broussolle, E, Madigand, M, Lallement, F, Goizet, C, Tison, F, Arguillère, S, Viallet, F, Bakchine, S, Khoris, J, Pages, M, Camu, W, Resch, F, Hannequin, D, Durif, F, Saudeau, D, Autret, A, Andrich, J, Saft, C, Kraus, Ph, Przuntek, H, Ecker, D, Kramer, B, Ludolph, Ac, Priller, J, Meierkord, H, Kuznik, D, Dose, M, Squitieri, F, Albanese, A, Abbruzzese, Giovanni, Filla, A, van de Warrenburg, B, de Jong, D, Kremer, H, van Vugt, J, Grimbergen, Y, Roos, R, Gawel, M, Janik, P, Kowalczys, H, Pilczuk, B, Kwiecinski, H, Swiat, M, Ochudło, S, Modestowicz, R, Niezgoda, A, Łukasik, M, Garcia de Yébenes, J, García Ruiz, P, Martínez Descals, A, Rojo, A, Fontán, A, Hernández, J, Cantarero, S, Fanjul, S, Alegre, J, Giménez Roldán, S, Mateo, D, Burguera, Ja, Solis, P, Calopa, M, Jaumà, S, Bas, J, Tolosa, E, Muñoz, Je, Gámez, J, Cervera, C, Zarranz, Jj, Lezcano, E, Gómez, Jc, Chacón, J, Dinca, L, Gamero, Ma, Redondo, L, Castro, A, Sesar, A, López del Val, J, López, E, Ríos, C, Castillio, V, Burgunder, Jm, Nirkko, A, Kälin, A, Vingerhoets, F, Wider, C., N. A., Aziz, J. M., M, G. B., Landwehrmeyer, P., Brundin, T., Stijnen, E. H. D., R. A. C., and Filla, Alessandro
- Subjects
Male ,Pathology ,therapeutic use, Nuclear Protein ,Neurology ,Disease ,Body Mass Index ,Placebos ,Mice ,Degenerative disease ,Trinucleotide Repeats ,Weight loss ,genetics ,Huntingtin Protein ,Riluzole ,Nuclear Proteins ,Middle Aged ,Huntington Disease ,Neuroprotective Agents ,Inbred C57BL, Mice ,genetics/metabolism, Placebos, Riluzole ,Female ,medicine.symptom ,Psychology ,Adult ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Mice, Transgenic ,Nerve Tissue Proteins ,Animal, Energy Intake, Female, Humans, Huntington Disease ,Central nervous system disease ,therapeutic use, Trinucleotide Repeats, Weight Lo ,Internal medicine ,Weight Loss ,mental disorders ,medicine ,Animals ,Humans ,Hereditary Neurodegenerative Disorder ,Transgenic, Middle Aged, Nerve Tissue Protein ,Aged ,drug therapy/genetics/physiopathology, Male, Mice, Mice ,Body Weight ,medicine.disease ,Adult, Aged, Animals, Body Mass Index, Body Weight, Disease Model ,Mice, Inbred C57BL ,Disease Models, Animal ,Endocrinology ,genetics/metabolism, Neuroprotective Agent ,Neurology (clinical) ,Energy Intake ,Body mass index - Abstract
Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded number of CAG repeats in the huntingtin gene. A hallmark of HD is unintended weight loss, the cause of which is unknown. In order to elucidate the underlying mechanisms of weight loss in HD, we studied its relation to other disease characteristics including motor, cognitive, and behavioral disturbances and CAG repeat number.In 517 patients with early stage HD, we applied mixed-effects model analyses to correlate weight changes over 3 years to CAG repeat number and various components of the Unified Huntington's Disease Rating Scale (UHDRS). We also assessed the relation between CAG repeat number and body weight and caloric intake in the R6/2 mouse model of HD.In patients with HD, mean body mass index decreased with -0.15 units per year (p < 0.001). However, no single UHDRS component, including motor, cognitive, and behavioral scores, was independently associated with the rate of weight loss. Patients with HD with a higher CAG repeat number had a faster rate of weight loss. Similarly, R6/2 mice with a larger CAG repeat length had a lower body weight, whereas caloric intake increased with larger CAG repeat length.Weight loss in Huntington disease (HD) is directly linked to CAG repeat length and is likely to result from a hypermetabolic state. Other signs and symptoms of HD are unlikely to contribute to weight loss in early disease stages. Elucidation of the responsible mechanisms could lead to effective energy-based therapeutics.
- Published
- 2008
10. [Cerebral achromatopsia without prosopagnosia, alexia, object agnosia]
- Author
-
Duvelleroy-Hommet C, Gillet P, Jean-Philippe Cottier, de Toffol B, Saudeau D, Corcia P, and Autret A
- Subjects
Humans ,Color Vision Defects ,Female ,Middle Aged ,Neuropsychological Tests ,Color Perception - Abstract
A 62-year-old woman was admitted for a disorder of color vision. This cerebral achromatopsia was isolated, without prosopagnosia, alexia, object agnosia. MRI showed bilateral temporo-occipital infarcts, including lingual and fusiform gyrus. Neuropsychological examination and topographic hypotheses are discussed.
- Published
- 1998
11. Exceptional stroke-like episodes in a patient with type I autosomal angioedema
- Author
-
Bonnaud, I., primary, Rouaud, V., additional, Guyot, M., additional, Debiais, S., additional, Saudeau, D., additional, de Toffol, B., additional, and Farber, C.-M., additional
- Published
- 2012
- Full Text
- View/download PDF
12. Fistule durale : une cause rare de démence curable à ne pas méconnaître
- Author
-
Deschasse, G., primary, Contentin, L., additional, Saudeau, D., additional, Hommet, C., additional, and Cottier, J.-P., additional
- Published
- 2009
- Full Text
- View/download PDF
13. Abrupt onset of disturbed vigilance, bilateral third nerve palsy and masturbating behaviour: a rare presentation of stroke
- Author
-
Mondon, K., primary, Bonnaud, I., additional, Debiais, S., additional, Brunault, P., additional, Saudeau, D., additional, de Toffol, B., additional, and Autret, A., additional
- Published
- 2007
- Full Text
- View/download PDF
14. G - 12 Causes de non thrombolyse chez les patients avec AVC admis dans les 3 premières heures
- Author
-
Bonnaud, I., primary, Debiais, S., additional, Giraudeau, B., additional, Saudeau, D., additional, Perrotin, D., additional, De Toffol, B., additional, and Autret, A., additional
- Published
- 2007
- Full Text
- View/download PDF
15. G - 46 Hémosidérose superficielle hémisphérique unilatérale : une présentation atypique
- Author
-
Limousin, N., primary, Bonnaud, I., additional, Cottier, J.-P., additional, Saudeau, D., additional, Autret, A., additional, and De Toffol, B., additional
- Published
- 2007
- Full Text
- View/download PDF
16. A spinal cord intravascular lymphomatosis with exceptionally good outcome
- Author
-
Debiais, S., primary, Bonnaud, I., additional, Cottier, J. P., additional, Destrieux, C., additional, Saudeau, D., additional, de Toffol, B., additional, Arbion, F., additional, Benboubker, L., additional, and Autret, A., additional
- Published
- 2004
- Full Text
- View/download PDF
17. Sleep and brain lesions: a critical review of the literature and additional new cases
- Author
-
Autret, A, primary, Lucas, B, additional, Mondon, K, additional, Hommet, C, additional, Corcia, Ph, additional, Saudeau, D, additional, and de Toffol, B, additional
- Published
- 2001
- Full Text
- View/download PDF
18. A double-blind, placebo-controlled, enriched population study of tacrine in patients with Alzheimer's disease
- Author
-
Forette, F., primary, Hoover, T., additional, Gracon, S., additional, Rotrou, J., additional, Hervy, M.P., additional, Lechevalier, B., additional, Micas, M., additional, Petit, H., additional, Orgogozo, J.M., additional, Guard, O., additional, Saudeau, D., additional, Forette, B., additional, Michel, B., additional, Emile, J., additional, Augustin, P., additional, Wang, A., additional, Vignat, J., additional, Allain, H., additional, Cuny, G., additional, Leger, J. M., additional, Collard, M., additional, Joyeux, O., additional, and Khalil, R., additional
- Published
- 1995
- Full Text
- View/download PDF
19. Idiopathic Hypereosinophilic Syndrome with a Radiologic Pattern of Central Pontine Myelinolysis
- Author
-
Menage, P., primary, de Toffol, B., additional, Saudeau, D., additional, Watier, H., additional, Bardos, P., additional, and Autret, A., additional
- Published
- 1995
- Full Text
- View/download PDF
20. Influence du sommeil sur les mouvements anormaux de la veille
- Author
-
Autret, A, primary, Lucas, B, additional, Henry, F, additional, Saudeau, D, additional, and de Toffol, B, additional
- Published
- 1994
- Full Text
- View/download PDF
21. Disseminated Aspergillosis in a Patient with Bronchiectasis.
- Author
-
Lemarié, E., Lemaire, B., Saudeau, D., Lavandier, M., Renoux, M., and Renoux, G.
- Published
- 1986
- Full Text
- View/download PDF
22. Epilepsies and time to diagnosis
- Author
-
Cachera, C., Baulac, M., Fagnani, F., Jallon, P., Leveau, J., Loiseau, P., Motte, J., Thomas, P., Vallee, L., Allaire, C., Autret, A., Baldy-Moulinier, M., Clanet, M., Dordain, G., Gastaut, J. L., Giroud, M., Josien, E., Marescaux, C., Masnou, P., Mauguiere, F., Parain, D., Perret, J., Revol, M., Rumbach, L., Tapie, P., Weber, M., Adam, C., Attal, N., Attane, F., Aubrun, P., Ayrivie, N., Badinand-Hubert, N., Bapst-Reiter, J., Barthez-Carpentier, M. A., Bartolomei, F., Bataillard, M., Bednarek, N., Belair, C., Benazet, M., Berges, S., Bergouignan, F. X., Bernard, C., Bernard-Bourzeix, L., Bertran, F., Bertrand, P., Beuriat, P., Billard, C., Bille-Turc, F., Billy, C., Biraben, A., Blanc, A., Boidein, F., Bouayed, N., Boudon, S., Bouillat, J., Boulloche, J., Bredin, A., Brocard, O., Brosset, P., Brunet-Bourgin, F., Cenraud, B., Chaigne, D., Chaix, Y., Chaunu, M. P., Chavot, D., Clavelou, P., Cohadon, S., Collombier, N., Contis, P. E., Convers, P., Couchot, J., Cournelle, M. A., Courtois, S., Croguennec, J. M., Cuisset, J. M., Cuvellier, J. C., D Anglejan, J., Damon, G., Danielli, A., Daubney, P., Bellescize, J., Lumley, L., Recondo, A., Swarte, M., Deffond, D., Delangre, T., Delisse, B., Derambure, P., Derambure, S., Desbordes, P., Desfrancois, F., Destee-Warot, M., Dien, J., Doremus, B., Dourneau-Lethiecq, M. C., Dubois, F., Duche, B., Ducrocq, X., Duhurt, J., Duprey, J., Durand, G., Dusser, A., Escaillas, J. P., Fanjaud, G., Felten, D., Fischer, C., Fontan, D., Formosa, F., Foulon, E., Furby, A., Gallet, S., Galmiche, J., Garde-Arthaud, P., Garrel, S., Gaultier, C., Gauthier, C., Gauthier-Morel, D., Genton, P., Geraud, G., Girard, J. P., Girard-Madoux, M., Gonnaud, P., Goulon-Goeau, C., Gros, S., Grosclaude, M., Gross, M., Gueguen, B., Guinot, H., Haenggeli, C. A., Hamon, J. B., Henlin, J. L., Hevin, B., Hinault, P., Homeyer, P., Hommet, C., Huart, E., Huc, P., Huttin, B., Inglesiakis, L., Isnard, J., Isnard, H., Jogeix, M., Juhel, C., Kahane, P., Kalafat, M., Keo-Kosal, P., Kreib, A. M., Kubler, C., Larrieu, E., Larrieu, J. L., Latinville, D., Le Gallou-Wittenberg, A., Lebas, F., Lebrun-Grandie, P., Leche, J., Legout, A., Legrand, S., Legroux, M., Lemaitre, J. F., Lestavel, P., Levasseur, M., Lienhard, C., Livet, M. O., Louiset, P., Lubeau, M., Lucas, B., Lucas-Daviaud, J., Maillard, S., Maillet-Vioud, M., Mancini, J., Mann, M., Marchal, C., Martini, L., Maupetit, J., Maynard, R., Menage, P., Menard, D., Metreau, R., Milor, M., Minot-Myhie, M. C., Moene, Y., Montagne, B., Montelescaut, M. E., Moreaud, O., Noelle, B., Olmi, X., Orbegozo, J., Ouvrard-Hernandez, A. M., Parsa, A., Pautrizel, B., Pedespan, J. M., Pernes, P., Perrouty, B., Petit, J., Peudenier, S., Picard, A. M., Pierrot-Deseilligny, C., Planque, E., Portha, C., Preux, P. M., Prud Homme, M., Raybaut-Guilhem, D., Rebaud, P., Regi, A., Regi, J. L., Reis, J., Rejou, F., Remy, C., Renard, J. F., Revenu, M., Revol, A., Rey, M., Richelme, C., Ricou, P., Rigal, J. P., Rogez, R., Rousselle, C., Rummens, C., Philippe Ryvlin, Sabouraud, P., Saikali, I., Saudeau, D., Savet, J. F., Schaeffer, J. L., Schaff, J. L., Schoenfelder, F., Schuermans, P., Senant, J., Setiey, A., Sevrin, C., Sivelle, G., Soisson, T., Soubielle, P., Soulages, X., Soulayrol, S., Tabaraud, F., Taillandier, P., Tannier, C., Tarel, V., Taussig, D., Thedrez, F., Tournier, C. L., Turc, J. D., Vanhulle, C., Vaunaize, J., Verier, A., Vernay, D., Visy, J. M., Vongsouthi, C., Vrigneaud, J., Waubant, E., Weichlein, A., Weill, O., Zai, L., Ziegler, F., Zix, C., Zelicourt, M., and Grp, Carole
23. High-dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme
- Author
-
Linassier C, Benboubker L, Stephane Velut, Calais G, Saudeau D, Jan M, Autret A, Berger C, Biron P, and Colombat P
- Subjects
Adult ,Male ,Humans ,Supratentorial Neoplasms ,Female ,Middle Aged ,Glioblastoma ,Antineoplastic Agents, Alkylating ,Carmustine ,Combined Modality Therapy ,Transplantation, Autologous ,Aged ,Bone Marrow Transplantation
24. Pes medullaires et corticaux chez le sujet normal et paraplegique
- Author
-
LAFFONT, F, primary, VIOLA, U, additional, AUTRET, A, additional, SAUDEAU, D, additional, and CHAUVET, M, additional
- Published
- 1985
- Full Text
- View/download PDF
25. STROKE RISK IN PATIENTS WITH CAROTID STENOSIS
- Author
-
Autret, A., primary, Saudeau, D., additional, Bertrand, PH., additional, Pourcelot, L., additional, Marchal, C., additional, and De Boisvilliers, S., additional
- Published
- 1987
- Full Text
- View/download PDF
26. D.H.E Methane Sulfonate With Programmed Liberation: Preliminary Results Of A Controlled Study In Common Migraine
- Author
-
Autret, A., de Chasteigner, C., Autret, A., de Chasteigner., C., Autret, E., Bertrand, Ph., Rabine, B., Mizon, J.P., Petit, H., Pradalier, A., Rascol, A., and Saudeau, D.
- Published
- 1987
- Full Text
- View/download PDF
27. How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease
- Author
-
Schramm, Catherine, Katsahian, Sandrine, Youssov, Katia, Démonet, Jean-François, Krystkowiak, Pierre, Supiot, Frédéric, Verny, Christophe, de Langavant, Laurent, Bachoud-Lévi, Anne-Catherine, Group, European, Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Unité de Biostatistiques, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d’informatique et statistiques, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Leenaards de la Mémoire, Université de Lausanne = University of Lausanne (UNIL)-CHUV, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Service de neurologie [Amiens], CHU Amiens-Picardie, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Centre de Référence des Maladies Neurogénétiques, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Service de neurologie [Mondor], Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de référence maladie de Huntington, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], Université de Lausanne (UNIL)-CHUV, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)-CHU Trousseau [APHP], Univ Angers, Okina, Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-CHU Pitié-Salpêtrière [APHP]-CHU Trousseau [APHP], Université de Lausanne ( UNIL ) -CHUV, Laboratoire de Neurosciences Fonctionnelles et Pathologies, Hôpital Roger Salengro-PRES Université Lille Nord de France-EA 4559/1046-Université de Lille, Droit et Santé, Hôpital Erasme, Université Libre de Bruxelles ( ULB ), Université Libre de Bruxelles [Bruxelles] ( ULB ), CHU Angers, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-CHU Pitié-Salpêtrière [APHP]-CHU Trousseau [APHP], Hôpital Erasme, Université Libre de Bruxelles (ULB), Université Libre de Bruxelles [Bruxelles] (ULB), European Huntington's Disease Initiative Study Group, the Multicentre Intracerebral Grafting in Huntington's Disease Group, Bachoud-Lévi, AC., Boissé, MF., Lemoine, L., Verny, C., Aubin, G., Demonet, JF., Calvas, F., Krystkowiak, P., Simonin, C., Delliaux, M., Damier, P., Renou, P., Supiot, F., Slama, H., Guillamo, J., Dürr, A., Bloch, F., Messouak, O., Tallaksen, C., Dubois, B., Engles, A., Destee, A., Memin, A., Thibaut-Tanchou, S., Pasquier, F., Galitzky, M., Rascol, O., Mollion, H., Broussolle, E., Madigand, M., Lallement, F., Goizet, C., Tison, F., Arguillère, S., Bakchine, S., Khoris, J., Camu, W., Resch, F., Hannequin, D., Durif, F., Saudeau, D., and Autret, A.
- Subjects
Adult ,Male ,Elementary cognitive task ,medicine.medical_specialty ,Psychologie appliquée ,lcsh:Medicine ,behavioral disciplines and activities ,Cohort Studies ,Cognition ,Huntington's disease ,Rating scale ,Models ,Medicine ,Dementia ,Humans ,Cognitive decline ,lcsh:Science ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,Multidisciplinary ,Models, Statistical ,business.industry ,Clinical study design ,lcsh:R ,Reproducibility of Results ,Sciences bio-médicales et agricoles ,Huntington disease ,Middle Aged ,Statistical ,medicine.disease ,3. Good health ,Clinical trial ,[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Physical therapy ,Disease Progression ,lcsh:Q ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Female ,business ,Biologie ,Algorithms ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Research Article - Abstract
The retest effect - improvement of performance on second exposure to a task - may impede the detection of cognitive decline in clinical trials for neurodegenerative diseases. We assessed the impact of the retest effect in Huntington's disease trials, and investigated its possible neutralization.We enrolled 54 patients in the Multicentric Intracerebral Grafting in Huntington's Disease (MIG-HD) trial and 39 in the placebo arm of the Riluzole trial in Huntington's Disease (RIL-HD). All were assessed with the Unified Huntington's Disease Rating Scale (UHDRS) plus additional cognitive tasks at baseline (A1), shortly after baseline (A2) and one year later (A3). We used paired t-tests to analyze the retest effect between A1 and A2. For each task of the MIG-HD study, we used a stepwise algorithm to design models predictive of patient performance at A3, which we applied to the RIL-HD trial for external validation. We observed a retest effect in most cognitive tasks. A decline in performance at one year was detected in 3 of the 15 cognitive tasks with A1 as the baseline, and 9 of the 15 cognitive tasks with A2 as the baseline.We also included the retest effect in performance modeling and showed that it facilitated performance prediction one year later for 14 of the 15 cognitive tasks. The retest effect may mask cognitive decline in patients with neurodegenerative diseases. The dual baseline can improve clinical trial design, and better prediction should homogenize patient groups, resulting in smaller numbers of participants being required., 0, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2015
- Full Text
- View/download PDF
28. Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial.
- Author
-
Mas JL, Arquizan C, Calvet D, Viguier A, Albucher JF, Piquet P, Garnier P, Viader F, Giroud M, Hosseini H, Hinzelin G, Favrole P, Hénon H, Neau JP, Ducrocq X, Padovani R, Milandre L, Rouanet F, Wolff V, Saudeau D, Mahagne MH, Sablot D, Amarenco P, Larrue V, Beyssen B, Leys D, Moulin T, Lièvre M, and Chatellier G
- Subjects
- Aged, Female, Follow-Up Studies, France, Humans, Male, Middle Aged, Prospective Studies, Risk, Stents, Treatment Outcome, Angioplasty methods, Carotid Stenosis surgery, Endarterectomy methods
- Abstract
Background and Purpose: We aimed at comparing the long-term benefit-risk balance of carotid stenting versus endarterectomy for symptomatic carotid stenosis., Methods: Long-term follow-up study of patients included in Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis (EVA-3S), a randomized, controlled trial of carotid stenting versus endarterectomy in 527 patients with recently symptomatic severe carotid stenosis, conducted in 30 centers in France. The main end point was a composite of any ipsilateral stroke after randomization or any procedural stroke or death., Results: During a median follow-up of 7.1 years (interquartile range, 5.1-8.8 years; maximum 12.4 years), the primary end point occurred in 30 patients in the stenting group compared with 18 patients in the endarterectomy group. Cumulative probabilities of this outcome were 11.0% (95% confidence interval, 7.9-15.2) versus 6.3% (4.0-9.8) in the endarterectomy group at the 5-year follow-up (hazard ratio, 1.85; 1.00-3.40; P=0.04) and 11.5% (8.2-15.9) versus 7.6% (4.9-11.8; hazard ratio, 1.70; 0.95-3.06; P=0.07) at the 10-year follow-up. No difference was observed between treatment groups in the rates of ipsilateral stroke beyond the procedural period, severe carotid restenosis (≥70%) or occlusion, death, myocardial infarction, and revascularization procedures., Conclusions: The long-term benefit-risk balance of carotid stenting versus endarterectomy for symptomatic carotid stenosis favored endarterectomy, a difference driven by a lower risk of procedural stroke after endarterectomy. Both techniques were associated with low and similar long-term risks of recurrent ipsilateral stroke beyond the procedural period., Clinical Trial Registration Url: http://www.clinicaltrials.gov. Unique identifier: NCT00190398., (© 2014 American Heart Association, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
29. Unexpected low prevalence of atrial fibrillation in cryptogenic ischemic stroke: a prospective study.
- Author
-
Dion F, Saudeau D, Bonnaud I, Friocourt P, Bonneau A, Poret P, Giraudeau B, Régina S, Fauchier L, and Babuty D
- Subjects
- Adolescent, Adult, Aged, Biomarkers blood, Echocardiography, Electrocardiography methods, Electrocardiography, Ambulatory, Electrophysiologic Techniques, Cardiac, Female, Humans, Incidence, Male, Middle Aged, Prevalence, Ultrasonography, Doppler, Atrial Fibrillation complications, Atrial Fibrillation epidemiology, Brain Ischemia epidemiology, Brain Ischemia etiology
- Abstract
Purpose: Ischemic stroke is a frequent pathology with high rate of recurrence and significant morbidity and mortality. There are several causes of stroke, affecting prognosis, outcomes, and management, but in many cases, the etiology remains undetermined. We hypothesized that atrial fibrillation was involved in this pathology but underdiagnosed by standard methods. The aim of the study was to determine the incidence of atrial fibrillation in cryptogenic ischemic stroke by using continuous monitoring of the heart rate over several months. The secondary objective was to test the value of atrial vulnerability assessment in predicting spontaneous atrial fibrillation., Methods and Results: We prospectively enrolled 24 patients under 75 years of age, 15 men and 9 women of mean age 49 years, who within the last 4 months had experienced cryptogenic stroke diagnosed by clinical presentation and brain imaging and presumed to be of cardioembolic mechanism. All causes of stroke were excluded by normal 12-lead ECG, 24-h Holter monitoring, echocardiography, cervical Doppler, hematological, and inflammatory tests. All patients underwent electrophysiological study. Of the patients, 37.5% had latent atrial vulnerability, and 33.3% had inducible sustained arrhythmia. Patients were secondarily implanted with an implantable loop recorder to look for spontaneous atrial fibrillation over a mean follow-up interval of 14.5 months. No sustained arrhythmia was found. Only one patient had non-significant episodes of atrial fibrillation., Conclusion: In this study, symptomatic atrial fibrillation or AF with fast ventricular rate has not been demonstrated by the implantable loop recorder in patients under 75 years with unexplained cerebral ischemia. The use of this device should not be generalized in the systematic evaluation of these patients. In addition, this study attests that the assessment of atrial vulnerability is poor at predicting spontaneous arrhythmia in such patients.
- Published
- 2010
- Full Text
- View/download PDF
30. Internal carotid artery dissection after tonsillectomy in an adult woman.
- Author
-
Bonnaud I, Cottier JP, Debiais S, Mondon K, Saudeau D, de Toffol B, and Autret A
- Subjects
- Carotid Artery, Internal, Dissection etiology, Carotid Artery, Internal, Dissection pathology, Cerebral Angiography, Female, Humans, Infarction, Middle Cerebral Artery pathology, Magnetic Resonance Angiography, Middle Aged, Severity of Illness Index, Tomography, X-Ray Computed, Carotid Artery, Internal, Dissection complications, Infarction, Middle Cerebral Artery etiology, Tonsillectomy adverse effects
- Published
- 2007
- Full Text
- View/download PDF
31. Isolated Horner's syndrome may herald stroke.
- Author
-
de Bray JM, Baumgartner R, Guillon B, Pautot V, Dziewas R, Ringelstein EB, Sturzenegger M, Garnier P, Ducrocq X, Saudeau D, Neau JP, Larrue V, Vuillier F, Boulliat J, Verret JM, Verny C, and Dubas F
- Subjects
- Adult, Cerebral Angiography, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Risk Factors, Horner Syndrome diagnosis, Horner Syndrome epidemiology, Stroke diagnosis, Stroke epidemiology
- Published
- 2005
- Full Text
- View/download PDF
32. Ischaemic strokes and homozygosity for the alpha2 807T allele of the platelet collagen receptor in young monozygotic twins.
- Author
-
Maakaroun A, Regina S, Delahousse B, Saudeau D, and Gruel Y
- Subjects
- Adult, Alleles, Blood Platelets chemistry, Family Health, Genotype, Homozygote, Humans, Integrin alpha2beta1 physiology, Male, Twins, Monozygotic, Diseases in Twins genetics, Integrin alpha2beta1 genetics, Polymorphism, Single Nucleotide, Stroke genetics
- Abstract
A nucleotide 807T variant of the glycoprotein Ia gene that correlates with increased platelet surface levels of the platelet collagen receptor alpha2beta1 was recently found to be associated with an increased risk of ischaemic stroke in younger patients. We report the history of twins who developed ischaemic strokes and were shown to be homozygous for the alpha2 807T allele. The twins developed ischaemic strokes at the ages of 23 and 33 years, one of them with recurrent events. They had no conventional risk factors. Cardiac and vascular investigations were normal and no aetiology could be found. There was a family history of cerebrovascular disease. Genotyping of glycoprotein alpha2 C807 T was performed and both twins were found to be homozygous for the 807T allele. This allele probably contributed to the occurrence of strokes in these young men. Further prospective studies are needed to evaluate whether screening for this polymorphism should be considered in young patients with unexplained stroke, particularly when a positive family history was found., (Copyright 2003 Lippincott Williams & Wilkins)
- Published
- 2003
- Full Text
- View/download PDF
33. Recurrence of spontaneous subdural haematoma revealing acquired haemophilia.
- Author
-
Bonnaud I, Saudeau D, de Toffol B, and Autret A
- Subjects
- Aged, Aged, 80 and over, Factor VIIa therapeutic use, Hematoma, Subdural diagnosis, Hematoma, Subdural physiopathology, Hematoma, Subdural surgery, Hemophilia A drug therapy, Hemophilia A physiopathology, Humans, Male, Recurrence, Tomography, X-Ray Computed, Hematoma, Subdural etiology, Hemophilia A complications
- Published
- 2003
- Full Text
- View/download PDF
34. Sleep and brain lesions: a critical review of the literature and additional new cases.
- Author
-
Autret A, Lucas B, Mondon K, Hommet C, Corcia P, Saudeau D, and de Toffol B
- Subjects
- Animals, Humans, Stroke complications, Brain Diseases physiopathology, Sleep physiology, Sleep Wake Disorders etiology, Stroke physiopathology
- Abstract
We present a comprehensive review of sleep studies performed in patients with brain lesions complemented by 16 additional personal selected cases and by discussion of the corresponding animal data. The reader is cautioned about the risk of establishing an erroneous correlation between abnormal sleep and a given disorder due to the important inter and intra variability of sleep parameters among individuals. Salient points are stressed: the high frequency of post-stroke sleep breathing disorders is becoming increasingly recognised and may, in the near future, change the way this condition is managed. Meso-diencephalic bilateral infarcts induce a variable degree of damage to both waking and non-REM sleep networks producing and abnormal waking and sometimes a stage 1 hypersomnia reduced by modafinil or bromocriptine, which can be considered as a syndrome of cathecholaminergic deficiency. Central pontine lesions induce REM and non-REM sleep insomnia with bilateral lateral gaze paralysis. Bulbar stroke leads to frequent sleep breathing disorders. Polysomnography can help define the extent of involvement of various degenerative diseases. Fragmented sleep in Parkinson's disease may be preceded by REM sleep behavioural disorders. Multiple system atrophies are characterised by important sleep disorganization. Sleep waking disorganization and a specific ocular REM pattern are often seen in supra-nuclear ophtalmoplegia. In Alzheimer patients, sleep perturbations parallel the mental deterioration and are possibly related to cholinergic deficiency. Fronto-temporal dementia may be associated with an important decrease in REM sleep. Few narcoleptic syndromes are reported to be associated with a tumour of the third ventricle or a multiple sclerosis or to follow a brain trauma; all these cases raise the question whether this is a simple coincidence, a revelation of a latent narcolepsy or, as in non-DR16/DQ5 patients, a genuine symptomatic narcolepsy. Trypanosomiasis and the abnormal prion protein precociously after sleep patterns. Polysomnography is a precious tool for evaluating brain function provided it is realised under optimal conditions in stable patients and interpreted with caution. Several unpublished cases are presented: one case of pseudohypersomnia due to a bilateral thalamic infarct and corrected by modafinil, four probable late-onset autosomal recessive cerebellar ataxias without sleep pattern anomalies, six cases of fronto-temporal dementia with strong reduction in total sleep time and REMS percentage on the first polysomnographic night, one case of periodic hypersomnia associated with a Rathke's cleft cyst and four cases of suspected symptomatic narcolepsy with a DR16-DQ5 haplotype, three of which were post-traumatic without MRI anomalies, and one associated with multiple sclerosis exhibiting pontine hyper signals on MRI.
- Published
- 2001
- Full Text
- View/download PDF
35. [Recommendations for the creation of neuro-vascular units].
- Author
-
Woimant F, Hommel M, Adnet Bonte C, Baldauf E, Chedru F, Cohen A, de Broucker T, Devailly JP, Duclos H, Gaston A, Grobuis S, Kassiotis P, Levasseur M, Merland JJ, Mounier Vehier F, Nibbio A, Orgogozo JM, Outin H, Pinel F, Pruvo JP, Rancurel G, Saudeau D, Scart-Gres C, Sévène M, Touboul PJ, Vassel P, Zuber M, Arquizan C, Baron JC, Becker F, Bes A, Boulliat J, Bousser MG, Bracard S, Branchereau A, Castel JP, Caussanel JP, Civit J, Collard M, Davoine P, Deroudille L, Dumas R, Frerebeau P, Giroud M, Goldstein P, Lagarrigue J, Lejeune JP, Lestavel P, Leys D, Mahagne MH, Manelfe C, Mas JL, Masson M, Michel D, Moulin T, Perret J, Petit H, Proust B, Rouanet F, Rougemont D, Roux FX, Samson Y, and Trouillas P
- Subjects
- Brain Ischemia diagnosis, Brain Ischemia therapy, France, Humans, Quality Assurance, Health Care, Stroke diagnosis, Stroke therapy
- Published
- 2001
36. [Cerebral achromatopsia without prosopagnosia, alexia, object agnosia].
- Author
-
Duvelleroy-Hommet C, Gillet P, Cottier JP, de Toffol B, Saudeau D, Corcia P, and Autret A
- Subjects
- Color Perception, Female, Humans, Middle Aged, Neuropsychological Tests, Color Vision Defects
- Abstract
A 62-year-old woman was admitted for a disorder of color vision. This cerebral achromatopsia was isolated, without prosopagnosia, alexia, object agnosia. MRI showed bilateral temporo-occipital infarcts, including lingual and fusiform gyrus. Neuropsychological examination and topographic hypotheses are discussed.
- Published
- 1997
37. High-dose BCNU with ABMT followed by radiation therapy in the treatment of supratentorial glioblastoma multiforme.
- Author
-
Linassier C, Benboubker L, Velut S, Calais G, Saudeau D, Jan M, Autret A, Berger C, Biron P, and Colombat P
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Glioblastoma drug therapy, Glioblastoma radiotherapy, Humans, Male, Middle Aged, Supratentorial Neoplasms drug therapy, Supratentorial Neoplasms radiotherapy, Transplantation, Autologous, Antineoplastic Agents, Alkylating administration & dosage, Bone Marrow Transplantation, Carmustine administration & dosage, Glioblastoma therapy, Supratentorial Neoplasms therapy
- Published
- 1996
38. [Convulsive seizures in a patient treated with propafenone and ketoconazole].
- Author
-
Duvelleroy Hommet C, Jonville-Bera AP, Autret A, Saudeau D, Autret E, and Fauchier JP
- Subjects
- Humans, Male, Middle Aged, Ketoconazole adverse effects, Propafenone adverse effects, Seizures chemically induced
- Published
- 1995
39. [The influence of sleep on abnormal waking movements].
- Author
-
Autret A, Lucas B, Henry F, Saudeau D, and de Toffol B
- Subjects
- Humans, Huntington Disease physiopathology, Parkinson Disease physiopathology, Tourette Syndrome physiopathology, Movement Disorders physiopathology, Sleep physiology, Wakefulness physiology
- Abstract
Sleep decreases considerably the abnormal movements seen during waking in the degenerative extra-pyramidal diseases. However, the electrophysiologic recordings reveal that muscular contractions are not completely abolished. This decrease parallels the reduction of the waking system which act likely as a non-specific system of amplification. One can notice that sleep modifies the characteristics of the parkinsonian tremor and that some palatal myoclonias persist during sleep.
- Published
- 1994
- Full Text
- View/download PDF
40. [Gougerot-Sjögren syndrome. Central neurological involvement with recurrent development].
- Author
-
Ménage P, de Toffol B, Degenne D, Saudeau D, Bardos P, and Autret A
- Subjects
- Antibodies, Antinuclear analysis, Central Nervous System Diseases diagnosis, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Recurrence, Central Nervous System Diseases etiology, Sjogren's Syndrome complications
- Abstract
A 64-year-old woman was repeatedly hospitalized for various recurrent clinical signs of central nervous system involvement. The diagnosis of primary Sjögren's syndrome was established 3 years 6 months after the onset of the disease. Sicca symptoms, as well as inflammatory biological abnormalities were absent. Moreover, both lacrymal and salivary gland secretions were affected. A high level of antinuclear antibodies to SSA and SSB was associated with inflammatory lesions in minor salivary glands biopsy samples consistent with the diagnosis of Sjögren's syndrome.
- Published
- 1993
41. Two mesencephalic lacunar infarcts presenting as Claude's syndrome and pure motor hemiparesis.
- Author
-
Gaymard B, Saudeau D, de Toffol B, Larmande P, and Autret A
- Subjects
- Aged, Cerebral Infarction diagnostic imaging, Female, Humans, Male, Middle Aged, Pyramidal Tracts diagnostic imaging, Red Nucleus diagnostic imaging, Tomography, X-Ray Computed, Cerebral Infarction complications, Hemiplegia etiology, Mesencephalon blood supply, Oculomotor Nerve Diseases etiology
- Abstract
Two exceptional cases of mesencephalic lacunar infarcts located both in the anterior vascular territory are reported. In patient 1, the infarct selectively involved the red nucleus, thus resulting in a Claude's syndrome. In patient 2, the lesion was limited to the external 2/3 of the cerebral peduncle, and was responsible for a pure motor hemiplegia (PMH). CT scan easily demonstrated the lesion in both cases. Claude's syndrome is very unusual, and PMH has only been reported once before in a mesencephalic infarct. The reasons why these lesions are so uncommon are discussed.
- Published
- 1991
- Full Text
- View/download PDF
42. [Outcome of intracranial meningioma in adults. Retrospective study of a medicosurgical series of 161 meningiomas].
- Author
-
Jan M, Bazézé V, Saudeau D, Autret A, Bertrand P, and Gouaze A
- Subjects
- Adult, Age Factors, Aged, Epilepsy etiology, Female, Humans, Male, Meningeal Neoplasms complications, Meningeal Neoplasms surgery, Meningioma complications, Meningioma surgery, Mental Disorders etiology, Middle Aged, Neoplasm Recurrence, Local etiology, Postoperative Complications etiology, Quality of Life, Retrospective Studies, Meningeal Neoplasms therapy, Meningioma therapy
- Abstract
The authors report the retrospective study of a medico-surgical series of 161 patients with intracranial meningiomas, diagnosed over a period of 9 years, with a follow-up period varying from 18 months to 9 years. Out of 185 cases studied, 24 were excluded because information or perspective were inadequate. Of the 161 cases retained, 133 (82.6%) were given surgical treatment and 28 (17.4%) were given conservative treatment because the clinical state was poor or the location was deemed inoperable. The sex ratio was 3 women to 1 man. The average age was 58 years. The most frequent locations were the convexity (27.9%) and the sphenoid ridge (24.7%). Among the clinical signs, apart from the usual general seizures or pyramidal signs should be noted the importance of psychological disorders. The operative mortality rate was 14.3% with a very high peak in the sixth decade, reaching 27%, while it was only 9% in the seventh decade and 13% in those over seventy. The internal sphenoid ridge location had a mortality rate of 31.5%, which is significantly higher than for all the other locations. Quality of survival was identical for all age groups. Complications were mainly seizures, functional deficits and psychological disorders. Recurrences were relatively few (10%), but insufficient lapse of time and the presence of only one malignant meningioma explain the lowness of this figure. The use of scanner was not determinant in our series, neither on the earliness of diagnosis, nor on prognosis, comparison of figures before and since scanning showing no significant differences.
- Published
- 1986
43. [Myoclonia caused by a combination of triprolidine, pseudoephedrine and paracetamol].
- Author
-
Jacquesson M, Saudeau D, Pantin B, Girard JJ, and Groussin P
- Subjects
- Drug Combinations adverse effects, Female, Humans, Middle Aged, Pseudoephedrine, Ephedrine adverse effects, Myoclonus chemically induced, Pyridines adverse effects, Triprolidine adverse effects
- Published
- 1982
44. [Preventive medical treatment of cerebral ischemic accidents related to atherosclerosis].
- Author
-
Saudeau D and Autret A
- Subjects
- Aspirin therapeutic use, Brain Ischemia etiology, Female, Humans, Hypertension therapy, Male, Middle Aged, Platelet Aggregation drug effects, Arteriosclerosis complications, Brain Ischemia prevention & control
- Published
- 1984
45. [Cerebrovascular accidents affecting the brain stem and evoked auditory potentials (author's transl)].
- Author
-
Robier A, Saudeau D, Autret A, and Reynaud J
- Subjects
- Brain Stem blood supply, Humans, Lateral Medullary Syndrome physiopathology, Brain Stem physiopathology, Cerebrovascular Disorders physiopathology, Evoked Potentials, Auditory
- Published
- 1981
46. [Atheroma: which carotids should be surgically treated?].
- Author
-
Autret A and Saudeau D
- Subjects
- Arteriosclerosis diagnosis, Arteriosclerosis mortality, Carotid Artery Diseases diagnosis, Carotid Artery Diseases mortality, Endarterectomy adverse effects, Endarterectomy mortality, Follow-Up Studies, Humans, Recurrence, Risk, Time Factors, Arteriosclerosis surgery, Carotid Arteries surgery, Carotid Artery Diseases surgery
- Abstract
Atheroma of the carotid bifurcation can be held responsible for 15% of the 150 000 cases of cerebrovascular attack recorded annually in France. Most of these are caused by an embolus detached from the thrombus formed around the atheromatous lesions. The natural history of asymptomatic carotid stenosis is imperfectly known because the patients are very heterogeneous. However, published series suggest that the risk of ischaemic complication in cases with more than 50% stenosis is about 0.7% per annum. No medical treatment has been tested against this disease. On the other hand, several uncontrolled studies have highlighted the therapeutic value of endarterectomy. The tendency towards surgery may become more widespread as non-invasive detection by ultrasounds is increasingly used. A randomized therapeutic trial is required to determine the value of this operation and the maximum tolerable morbidity rate. In the case of transient ischaemic attacks, a joint study on extracranial arterial occlusion has demonstrated the value of successful endarterectomy and shown that the maximum tolerable morbidity from surgery is 3%. Slightly higher figures are probably acceptable for cases with tight stenosis. Such an approach cannot determine whether endarterectomy would be of value in completed stroke, because the pathological conditions involved are extremely variable. Reasoning by analogy with transient ischaemic attacks, it would seem that tight or ulcerated stenoses could benefit from the operation some time after a regressive stroke. Ultrasonic techniques and intravenous angiography have made examination of the cervical arteries considerably easier. The risk of wounding the left carotid artery should be carefully weighed. Preoperative cardiac assessment is necessary in view of the high incidence of heart disease in the follow-up of these patients. Thus, natural history data set high standards for surgical performance and less risk for pre-operative investigations.
- Published
- 1986
47. [A case of familial muscle weakness corrected by exercise (author's transl)].
- Author
-
Sabouraud O, Pinel JF, Le Bars R, Menault F, and Saudeau D
- Subjects
- Diagnosis, Differential, Electromyography, Exercise Therapy, Humans, Male, Middle Aged, Myotonia Congenita diagnosis, Myotonia Congenita genetics, Myotonia Congenita therapy
- Abstract
The symptom described as muscle weakness corrected by exercise appears to be part of the recessive form of congenital myotonia, of which it can constitute the dominant clinical manifestation in some cases. This symptom coincides with decrements of the action of potentials to repetitive stimulations in the electromyogram, which may be particularly severe in these same cases. These observations contribute to the modification and precision of the description of the recessive form of Thomsen's disease, but their pathogenicity remains unclear.
- Published
- 1979
48. [Complicated migraine, epilepsy and tomodensitometric hypodensity].
- Author
-
Saudeau D, Larmande P, Odier F, and Autret A
- Subjects
- Adult, Blood-Brain Barrier, Brain diagnostic imaging, Brain Ischemia complications, Female, Humans, Male, Middle Aged, Migraine Disorders diagnostic imaging, Epilepsy etiology, Migraine Disorders complications, Tomography, X-Ray Computed
- Published
- 1982
49. [Spinal and cortical SEP's in healthy subjects and paraplegics].
- Author
-
Laffont F, Viola U, Autret A, Saudeau D, and Chauvet MA
- Subjects
- Adult, Cerebral Cortex physiopathology, Female, Humans, Hypesthesia physiopathology, Male, Middle Aged, Neural Conduction, Reaction Time physiology, Spinal Cord physiopathology, Evoked Potentials, Somatosensory, Nervous System physiopathology, Paraplegia physiopathology
- Abstract
SEPs are evoked by electrical stimulation of tibial nerve in the fossa poplitea. Surface electrodes, located in S1, L4, L2, T12 with a reference in T6, can record lumbar evoked potentials and calculate a peripheral sensitive velocity. Bipolar leads between electrodes located in T12, T9, T6, T3 and C7 record medullary potential and calculate a medullary transit velocity. The cortical potential is monitored between C'z and a non-cephalic reference. 25 controls and 10 paraplegic patients are studied. In controls, sensitive peripheral velocity is 59 m/sec. The lumbar potential is composed of two negative waves, respectively due to the activation of sensitive roots and to the medullary potential. The medullary transit velocity, measured by the increase of the latency of the culmination of this negative wave along the spine, is 60 m/sec. The cortical potential is composed of two stable waves P30 N38 which are observed in every control; these waves are followed by a succession of positive and negative waves. In the 10 paraplegic patients, complete anesthesia observed in 5 cases is associated with an absence of cortical potential, and the hypoesthesia observed in 5 cases is associated with a cortical potential with a reduced amplitude (2 cases) or an increased latency (3 cases). In these last 3 cases, the medullary potential allows to specify the location of slowing of the transit velocity.
- Published
- 1985
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.